Example: Heart Attack

Search clinical trials for: Gemtuzumab

Total 100 results

NCT00860639

Completed

Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk

Conditions: Acute Myeloid Leukemia
NCT04337138

Completed

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Conditions: Leukemia, Myeloid, Acute
NCT02221310

Recruiting

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
NCT03727750

Recruiting

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

Conditions: ECG; Pharmacokinetics; Safety
NCT02473146

Unknown status

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4

Conditions: Acute Myeloid Leukemia
NCT03374332

Recruiting

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03737955

Recruiting

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or High-Risk Myeloproliferative Neoplasm

Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm
NCT03839446

Recruiting

Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy

Conditions: Acute Myeloid Leukemia
NCT03848754

Recruiting

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Conditions: Relapsed Adult AML
NCT02117297

Recruiting

SCT Plus Immune Therapy in Average Risk AML/MDS

Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
NCT00882102

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
NCT04070768

Recruiting

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Conditions: Acute Myeloid Leukemia
NCT00968071

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Conditions: Acute Myelogenous Leukemia; Myelodysplastic Syndrome
NCT02182596

Completed

DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML

Conditions: Acute Myeloid Leukemia
NCT04168502

Not yet recruiting

Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Conditions: Acute Myeloid Leukemia
NCT03904251

Recruiting

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Conditions: Acute Myelogenous Leukemia
NCT01548911

Withdrawn

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia
NCT00274781

Completed

Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes

Conditions: Leukemia; Myelodysplastic Syndromes
NCT00766116

Completed

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloid Leukemia
NCT01041040

Completed

LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)

Conditions: Acute Myeloblastic Leukemia
NCT00476541

Completed

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia

Conditions: Acute Myeloid Leukemia
NCT03672539

Recruiting

Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; High Risk Myelodysplastic Syndrome; Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT03878927

Recruiting

CPX-351+GO in Subjects 55 Years Old, or Older, With AML

Conditions: Acute Myeloid Leukemia
NCT04050280

Recruiting

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Conditions: Acute Myeloid Leukemia, Adult; Acute Myeloid Leukemia Recurrent; Acute Myeloid Leukemia, Relapsed, Adult
NCT00038805

Terminated

Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS)

Conditions: Leukemia